Degarelix
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $12,500 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,500 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist | Ferring Pharmaceuticals AS | $12,500 | 0 |
Top Doctors Receiving Payments for Degarelix
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Kansas City, KS | $12,500 | 1 |
Manufacturing Companies
- Ferring Pharmaceuticals AS $12,500
Product Information
- Type Drug
- Total Payments $12,500
- Total Doctors 0
- Transactions 1
About Degarelix
Degarelix is a drug associated with $12,500 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals AS.
Payment data is available from 2018 to 2018. In 2018, $12,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for Degarelix is "Unspecified" ($12,500, 100.0% of total).
Degarelix is associated with 1 research study, including "A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist" ($12,500).